

IN THE SPECIFICATION:

Pursuant to 37 C.F.R. §§ 1.121 and 1.125 (as amended to date) please enter the substitute specification in clean form and including paragraph numbers [0001] through [0196], references, tables and Abstract attached hereto as Appendix A. A marked-up substitute specification to clearly identify amendments to the specification as required by 37 C.F.R. § 1.121(b)(3)(iii) is attached hereto as Appendix B. It is respectfully submitted that the substitute specification does not introduce new matter into the above-referenced patent application.

Please add the attached sequence listing to the above referenced application after the claims.

IN THE CLAIMS:

Please cancel claims 2, 4, 8, 9, 18-21, 23-34, 37-41, 43, 45, 47, 49, 51-54, 57, 58, 63, 64, and 69-72 without prejudice or disclaimer.

B¹
5. (Twice amended) The method according to claim 1, wherein at least one of the proteinaceous substance harvested is encoded by said gene.

B²
7. (Twice amended) The method according to claim 1, wherein said at least one adenoviral E1 protein comprises an E1A protein or a functional homologue, fragment and/or derivative thereof.

B³
11. (Twice amended) The method according to claim 1, wherein said proteinaceous substance is a protein that undergoes post-translational and/or peri-translational modification.

B⁴
13. (Twice amended) The method according to claim 1, wherein said proteinaceous substance is erythropoietin.